Xenon Pharmaceuticals Inc. (XENE)
Largest Insider Buys in Sector
XENE Stock Price History Chart
XENE Stock Performance
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Insider Activity of Xenon Pharmaceuticals Inc.
Over the last 12 months, insiders at Xenon Pharmaceuticals Inc. have bought $0 and sold $3.07M worth of Xenon Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Xenon Pharmaceuticals Inc. have bought $235,534 and sold $4.04M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,400 shares for transaction amount of $40,334 was made by KENNEY CHRISTOPHER JOHN (Chief Medical Officer) on 2022‑01‑21.
List of Insider Buy and Sell Transactions, Xenon Pharmaceuticals Inc.
| 2024-03-08 | Sale | GAROFALO ELIZABETH A. | director | 2,092 0.0027% | $45.69 | $95,583 | -12.06% | |
| 2024-03-07 | Sale | ROBIN SHERRINGTON | EVP, Strategy & Innovation | 7,137 0.0095% | $46.28 | $330,290 | -11.72% | |
| 2024-03-07 | Sale | GANNON STEVEN | director | 13,000 0.0173% | $46.28 | $601,615 | -11.72% | |
| 2023-12-14 | Sale | PATOU GARY | director | 7,598 0.0103% | $41.05 | $311,898 | +4.34% | |
| 2023-12-13 | Sale | PATOU GARY | director | 18,978 0.0257% | $39.99 | $758,983 | +7.89% | |
| 2023-08-24 | Sale | Svoronos Dawn | director | 25,000 0.0391% | $38.70 | $967,500 | +4.46% | |
| 2023-06-01 | Sale | PIMSTONE SIMON N. | director | 31,713 0.0485% | $38.82 | $1.23M | +2.68% | |
| 2023-05-31 | Sale | PIMSTONE SIMON N. | director | 62,526 0.0956% | $38.70 | $2.42M | +2.88% | |
| 2023-05-30 | Sale | PIMSTONE SIMON N. | director | 37,006 0.0576% | $39.28 | $1.45M | +3.31% | |
| 2023-05-24 | Sale | MORTIMER IAN | PRESIDENT & CEO | 31,655 0.0482% | $41.41 | $1.31M | -3.86% | |
| 2023-03-24 | Sale | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 700 0.0011% | $35.01 | $24,507 | +10.93% | |
| 2023-03-07 | Sale | PIMSTONE SIMON N. | director | 19,232 0.03% | $36.98 | $711,199 | +6.69% | |
| 2022-11-25 | Sale | PATOU GARY | director | 1,937 0.0032% | $34.79 | $67,390 | +8.16% | |
| 2022-09-02 | Sale | AULIN SHERRY | Chief Financial Officer | 15,355 0.0238% | $39.57 | $607,597 | -3.33% | |
| 2022-08-31 | Sale | ROBIN SHERRINGTON | EVP, Strategy & Innovation | 8,776 0.0134% | $38.80 | $340,509 | -2.80% | |
| 2022-08-12 | Sale | PIMSTONE SIMON N. | 32,058 0.0495% | $38.29 | $1.23M | -0.50% | ||
| 2022-08-12 | Sale | EMPFIELD JAMES R. | EVP, Drug Discovery | 21,875 0.0341% | $38.68 | $846,125 | -0.50% | |
| 2022-03-08 | Sale | PIMSTONE SIMON N. | director | 5,000 0.0092% | $30.80 | $154,000 | +17.14% | |
| 2022-03-07 | Sale | PIMSTONE SIMON N. | director | 31,086 0.0572% | $30.50 | $948,260 | +18.01% | |
| 2022-03-07 | Sale | EMPFIELD JAMES R. | EVP, Drug Discovery | 32,853 0.0606% | $30.54 | $1M | +18.01% |
Insider Historical Profitability
| Svoronos Dawn | director | 25000 0.0338% | $36.57 | 1 | 1 | +44.5% |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 8398 0.0227% | $36.57 | 0 | 4 | |
| GANNON STEVEN | director | 2000 0.0203% | $36.57 | 1 | 1 | +31.48% |
| PATOU GARY | director | 4902 0.0066% | $36.57 | 2 | 3 | +22.07% |
| GAROFALO ELIZABETH A. | director | 0 0% | $36.57 | 0 | 1 | |
| BVF PARTNERS L P/IL | 10 percent owner | 1674468 2.2661% | $36.57 | 10 | 0 | <0.0001% |
| Hayden Michael R | director | 161187 0.2181% | $36.57 | 1 | 0 | +44.5% |
| HOLLER FRANK A | director | 143653 0.1944% | $36.57 | 0 | 10 | |
| AZAB MOHAMMAD | director | 57561 0.0779% | $36.57 | 5 | 1 | +72.32% |
| MORTIMER IAN | PRESIDENT & CEO | 24213 0.0328% | $36.57 | 2 | 1 | +28.18% |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 10000 0.0135% | $36.57 | 1 | 3 | +48.47% |
| SCHELLER RICHARD H | director | 7000 0.0095% | $36.57 | 1 | 0 | +28.18% |
| GOLDBERG Y. PAUL | VP of Clinical Development | 6000 0.0081% | $36.57 | 0 | 3 | |
| PIMSTONE SIMON N. | director | 6000 0.0081% | $36.57 | 1 | 12 | +28.18% |
| Von Seggern Christopher | Chief Commercial Officer | 4000 0.0054% | $36.57 | 1 | 0 | +29.4% |
| WINQUIST RAYMOND | Head, Translational Research | 1000 0.0014% | $36.57 | 1 | 0 | +25.42% |
| AULIN SHERRY | Chief Financial Officer | 0 0% | $36.57 | 0 | 1 | |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 0 0% | $36.57 | 1 | 1 | +29.65% |
Institutional Investor Ownership
| Fidelity Investments | $284.21M | 8.75 | 6.6M | +16.72% | +$40.72M | 0.02 | |
| Avoro Capital Advisors Llc | $243.95M | 7.51 | 5.67M | 0% | +$0 | 2.92 | |
| Driehaus Capital Management LLC | $186.05M | 5.73 | 4.32M | -0.54% | -$1.01M | 1.86 | |
| Wellington Management Company | $168.84M | 5.2 | 3.92M | -5.78% | -$10.36M | 0.03 | |
| Capital World Investors | $115.44M | 3.55 | 2.68M | 0% | +$0 | 0.02 | |
| Polar Capital | $112.45M | 3.46 | 2.61M | -14.82% | -$19.57M | 0.62 | |
| Paradigm BioCapital Advisors LP | $106.97M | 3.29 | 2.48M | +16.8% | +$15.39M | 3.88 | |
| Capital International Investors | $106.59M | 3.28 | 2.48M | +0.82% | +$868,576.80 | 0.02 | |
| Commodore Capital, LP | $93.32M | 2.87 | 2.17M | 0% | +$0 | 6.58 | |
| BlackRock | $91.35M | 2.81 | 2.12M | +2.65% | +$2.36M | <0.01 | |
| Adage Capital Partners Gp L L C | $71.98M | 2.22 | 1.67M | +59.42% | +$26.83M | 0.13 | |
| AllianceBernstein | $63.22M | 1.95 | 1.47M | -6.74% | -$4.57M | 0.02 | |
| Marshall Wace | $62.44M | 1.92 | 1.45M | -5.12% | -$3.37M | 0.08 | |
| T Rowe Price Investment Management Inc | $61.4M | 1.89 | 1.43M | +60.06% | +$23.04M | 0.04 | |
| First Light Asset Management | $56.83M | 1.75 | 1.32M | -19.77% | -$14M | 4.49 | |
| Braidwell Lp | $56.31M | 1.73 | 1.31M | -20.6% | -$14.61M | 3.17 | |
| Citadel Advisors LLC | $55.41M | 1.71 | 1.29M | +1.6% | +$870,944.55 | 0.04 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $54.05M | 1.66 | 1.26M | 0% | +$0 | 1.38 | |
| Invesco | $45.18M | 1.39 | 1.05M | +45.83% | +$14.2M | 0.01 | |
| Baker Bros Advisors LP | $42.78M | 1.32 | 993,679 | 0% | +$0 | 0.54 | |
| Janus Henderson | $40.55M | 1.25 | 941,569 | -2.54% | -$1.05M | 0.02 | |
| Lord Abbett | $38.54M | 1.19 | 895,196 | +24.68% | +$7.63M | 0.13 | |
| Perceptive Advisors | $38.41M | 1.18 | 892,208 | -18.95% | -$8.98M | 0.03 | |
| Affinity Asset Advisors | $36.05M | 1.11 | 837,387 | +82.04% | +$16.25M | 6.4 | |
| TimesSquare Capital Management LLC | $31.73M | 0.98 | 737,173 | -7.15% | -$2.44M | 0.46 | |
| Federated Hermes | $31.64M | 0.97 | 734,900 | +112.03% | +$16.72M | 0.07 | |
| Avidity Partners Management Lp | $30.57M | 0.94 | 710,000 | -12.99% | -$4.56M | 1.11 | |
| Loomis, Sayles & Company | $29.55M | 0.91 | 686,510 | -3.08% | -$937,836.14 | 0.04 | |
| Boxer Capital, LLC | $25.83M | 0.8 | 600,000 | 0% | +$0 | 1.29 | |
| Fiera Capital | $24.82M | 0.76 | 576,542 | +4.25% | +$1.01M | 0.07 | |
| JENNISON ASSOCIATES LLC | $24.28M | 0.75 | 563,952 | -0.43% | -$105,214.21 | 0.02 | |
| Candriam S C A | $24.15M | 0.74 | 560,884 | +5.65% | +$1.29M | 0.16 | |
| OrbiMed | $23.68M | 0.73 | 550,000 | 0% | +$0 | 0.48 | |
| Franklin Templeton Investments | $23.35M | 0.72 | 542,289 | +84.56% | +$10.7M | 0.01 | |
| Great Point Partners | $19.64M | 0.6 | 456,148 | -23.98% | -$6.19M | 3.29 | |
| Dimensional Fund Advisors | $17.66M | 0.54 | 410,207 | +1.87% | +$324,553.94 | 0.01 | |
| Samlyn Capital, LLC | $17.06M | 0.53 | 396,196 | -5.93% | -$1.07M | 0.3 | |
| Morgan Stanley | $16.63M | 0.51 | 386,199 | +71.53% | +$6.93M | <0.01 | |
| Altium Capital Management Lp | $14.98M | 0.46 | 348,000 | +19.78% | +$2.47M | 6.97 | |
| Westfield Capital Management Co Lp | $14.95M | 0.46 | 347,351 | +46.26% | +$4.73M | 0.08 | |
| The Vanguard Group | $14.45M | 0.45 | 335,635 | +3.75% | +$522,626.97 | <0.0001 | |
| Ally Bridge Group | $13.32M | 0.41 | 309,369 | +27.86% | +$2.9M | 7.49 | |
| Goldman Sachs | $12.91M | 0.4 | 299,774 | -20.34% | -$3.29M | <0.01 | |
| Boone Capital Management Llc | $12.54M | 0.39 | 291,403 | +14.08% | +$1.55M | 2.54 | |
| Point72 Asset Management | $11.88M | 0.37 | 275,859 | -68.48% | -$25.8M | 0.02 | |
| Two Sigma | $11.82M | 0.36 | 274,626 | -19.23% | -$2.81M | 0.02 | |
| DAFNA Capital Management, LLC | $11.78M | 0.36 | 273,739 | -1.08% | -$129,150.00 | 2.74 | |
| Artal Group S A | $10.91M | 0.34 | 253,387 | New | +$10.91M | 0.06 | |
| Granahan Investment Management | $10.51M | 0.32 | 244,080 | -19.33% | -$2.52M | 0.37 | |
| State Street | $10.45M | 0.32 | 242,640 | +6.87% | +$671,580.00 | <0.0001 |